BioParity.UFO / UAP research

6 papers for “Cell signaling”

Results

PaperS7696

Variation of Immune Cell Responses in Humans Reveals Sex-Specific Coordinated Signaling Across Cell Types

Gabriela K. Fragiadakis, Zachary B. Bjornson-Hooper, Deepthi Madhireddy, Karen Sachs, Han Chen, David R. McIlwain, Matthew H. Spitzer, Sean C. Bendall, Garry P. Nolan. pmc.ncbi.nlm.nih.gov. March 28, 2022.

This healthy-donor study describes correlated immune responses and sex-associated differences within one cohort. Its reported prediction tests use donors from that same cohort; clinical or causal conclusions are not established. Root reviewed results, discussion, captions and declarations, with the entire Methods section excluded. FDA contracts are acknowledged at work level without identifying Nolan as their individual recipient. Nolan advised and edited the study; these public acknowledgements do not establish a classified UAP approach.

Partial root supplied XML text; Methods excluded
PaperS7598

TRAIL-induced variation of cell signaling states provides nonheritable resistance to apoptosis

Reema Baskar, Harris G Fienberg, Zumana Khair, Patricia Favaro, Sam Kimmey, Douglas R Green, Garry P Nolan, Sylvia Plevritis, Sean C Bendall. ebi.ac.uk. November 8, 2019.

This cultured-cell study examines variation in resistance to TRAIL-induced apoptosis. Responses differ across cell lines, and no universal resistant signaling state emerged. Reviewers questioned replication, causality and selected-marker diversity; the revised paper and small surviving fractions retain those limits.

Complete supplied main text and qualified apparatus reviewed
PaperS7613

Cellular Signaling Analysis shows antiviral, ribavirin-mediated ribosomal signaling modulation

Xianting Ding, Peter O Krutzik, Amir Ali Ghaffari, Yixiu Zhaozhi, Daniel Miranda Jr, Genhong Cheng, Chih-Ming Ho, Garry P Nolan, David Jesse Sanchez. ebi.ac.uk. September 9, 2019.

The authors connect antiviral treatment, infection and ribosomal signaling in selected cell assays and a short mouse model. Timing, inadequate low-dose response, broad effects at higher doses, declining viability and delayed animal results qualify the mechanism. These findings do not demonstrate treatment benefit or safety in people.

Complete supplied main and meaningful images; raw study unreviewed
PaperS7583

SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia

Jolanda Sarno, Angela M Savino, Chiara Buracchi, Chiara Palmi, Stefania Pinto, Cristina Bugarin, Astraea Jager, Silvia Bresolin, Ruth C Barber, Daniela Silvestri, Shai Israeli, Martin JS Dyer, Giovanni Cazzaniga, Garry P Nolan, Andrea Biondi, Kara L Davis, Giuseppe Gaipa. ebi.ac.uk. May 1, 2018.

A preclinical leukemia study reports signaling and cell-viability responses to SRC/ABL inhibition. Results vary across selected samples, cell models and treatment conditions. Negative findings, limited sample availability and statistical inconsistencies qualify the claims. The supplied main text and supplement are read; clinical effectiveness and UAP relevance are not established.

Supplied main text and supplement read; original main layout incomplete
PaperS7587

DRUG-NEM: Optimizing drug combinations using single-cell perturbation response to account for intratumoral heterogeneity

Benedict Anchang, Kara L. Davis, Harris G. Fienberg, Brian D. Williamson, Sean C. Bendall, Loukia G. Karacosta, Robert Tibshirani, Garry P. Nolan, Sylvia K. Plevritis. ebi.ac.uk. April 13, 2018.

DRUG-NEM ranks drug combinations using selected single-cell signaling responses. Its short-term surrogates and fixed-subpopulation assumptions limit interpretation. Repeated analyses are not new patients, and cell-line validation does not establish clinical benefit. The supplied main text is read; supporting information remains missing.

Supplied main text and mathematics read; apparatus partial
PaperS7558

Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy

Nitya Nair, Henrik E. Mei, Shih-Yu Chen, Matthew Hale, Garry P. Nolan, Holden T. Maecker, Mark Genovese, C. Garrison Fathman, Chan C. Whiting. ebi.ac.uk. May 18, 2015.

This 2015 review discusses mass cytometry as a possible aid to rheumatic-disease research. Its preliminary illustration compares one patient with one healthy control; concurrent treatment and assay timing limit interpretation. The authors explicitly consider residual drug neutralizing added TNF as an alternative to changed cell signaling. The illustration does not establish a validated biomarker or clinical recommendation. Nolan is a verified coauthor, while detailed individual contribution roles are not supplied.

Complete supplied review text and figures read

A curated public selection. Source review describes what was read; it does not establish that a claim is true. Our research approach